Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells

Immunology Letters

Volumn 131, Issue 1, 2010, Pages 24-32

  Spies, Cornelia M ^a   Gaber, Timo ^a,b   Hahne, Martin ^a,b   Naumann, Lydia ^a   Tripmacher, Robert ^a   Schellmann, Saskia ^a,b   Stahn, Cindy ^a,b   Burmester, Gerd Rüdiger ^a   Radbruch, Andreas ^b   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

CD4 expression; Cytokine; Dexamethasone; Genomic; Glucocorticoid; Non genomic; Proliferation; Rimexolone; T cells

Indexed keywords

ANTIBODY; CD28 ANTIBODY; CD3 ANTIBODY; CD4 ANTIGEN; CYTOKINE; DEXAMETHASONE; I KAPPA B ALPHA; INTERLEUKIN 2; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RIMEXOLONE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIVISION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INCUBATION TIME; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; LYMPHOCYTE ACTIVATION; PREGNADIENES; SIGNAL TRANSDUCTION;

EID: 77954757173     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.03.009     Document Type: Article

References (21)

1. van Vliet-Daskalopoulou E., Jentjens T., Scheffer R.T. Intra-articular rimexolone in the rheumatoid knee: a placebo-controlled, double-blind, multicentre trial of three doses. Br J Rheumatol 1987, 26:450-453.
2. Biswas J., Ganeshbabu T.M., Raghavendran S.R., Raizada S., Mondkar S.V., Madhavan H.N. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis-a randomized triple masked study. Int Ophthalmol 2004, 25:147-153.
3. Kavuncu S., Horoz H., Ardagil A., Erbil H.H. Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. Int Ophthalmol 2008, 28:281-285.
4. Fox P.K., Lewis A.J., Rae R.M., Sim A.W., Woods G.F. The biological properties of Org 6216, a new type of steroid with a selective local anti-inflammatory action. Arzneimittelforschung 1980, 30:55-59.
5. Derendorf H., Mollmann H., Voortman G., van den Ouweland F.A., van de Putte L.B., Gevers G., et al. Pharmacokinetics of rimexolone after intra-articular administration. J Clin Pharmacol 1990, 30:476-479.
6. Hochhaus G., Moellmann H.W. Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions 1990, 30:377-380.
7. Buttgereit F., Straub R.H., Wehling M., Burmester G.R. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004, 50:3408-3417.
8. Almawi W.Y., Beyhum H.N., Rahme A.A., Rieder M.J. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996, 60:563-572.
9. Buttgereit F., da Silva J.A., Boers M., Burmester G.R., Cutolo M., Jacobs J., et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002, 61:718-722.
10. Löwenberg M., Stahn C., Hommes D.W., Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008, 73:1025-1029.
11. Löwenberg M., Verhaar A.P., van den Brink G.R., Hommes D.W. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007, 13:158-163.
12. Löwenberg M., Tuynman J., Bilderbeek J., Gaber T., Buttgereit F., van Deventer S., et al. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 2005, 106:1703-1710.
13. Löwenberg M., Verhaar A.P., Bilderbeek J., Marle J., Buttgereit F., Peppelenbosch M.P., et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006, 7:1023-1029.
14. Morgan E., Varro R., Sepulveda H., Ember J.A., Apgar J., Wilson J., et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 2004, 110:252-266.
15. Nicholson D.W., Thornberry N.A. Caspases: killer proteases. Trends Biochem Sci 1997, 22:299-306.
16. Shimizu T., Pommier Y. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 1997, 11:1238-1244.
17. Lewis A.J. The local anti-inflammatory activity of rimexolone (Org 6216) in fibrin-induced monoarticular arthritis and adjuvant-induced arthritis. Agents Actions 1980, 10:258-265.
18. Buttgereit F., Brand M.D., Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999, 58:363-368.
19. Wiegers G.J., Stec I.E., Klinkert W.E., Reul J.M. Glucocorticoids regulate TCR-induced elevation of CD4: functional implications. J Immunol 2000, 164:6213-6220.
20. Wiegers G.J., Stec I.E., Klinkert W.E., Linthorst A.C., Reul J.M. Bidirectional effects of corticosterone on splenic T-cell activation: critical role of cell density and culture time. Neuroendocrinology 2001, 73:139-148.
21. Tsukadaira A., Okubo Y., Horie S., Koyama S. Theophylline inhibits TNF-α-induced CD4 expression on human eosinophils and CD4+ eosinophil migration. Int Arch Allergy Immunol 2001, 125:335-343.